CD66c antibody
- Known as:
- CD66c (anti-)
- Catalog number:
- orb100511
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- CD66c antibody
Related genes to: CD66c antibody
- Gene:
- CEACAM6 NIH gene
- Name:
- carcinoembryonic antigen related cell adhesion molecule 6
- Previous symbol:
- NCA
- Synonyms:
- CD66c
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2016-10-05
Related products to: CD66c antibody
Related articles to: CD66c antibody
- Severe acute pancreatitis (SAP) is associated with persistent organ failure and substantial mortality, yet the transcriptomic mechanisms underlying progression from mild acute pancreatitis to severe-spectrum disease remain incompletely defined. Early identification of patients at risk of persistent organ failure remains an important unmet clinical need. - Source: PubMed
Publication date: 2026/09/25
He YaobinLiu KairuiChen RongHuang YipeiHuang Youxing - As leptomeningeal metastasis (LM) has a poor prognosis, reliable cerebrospinal fluid (CSF) diagnostic biomarkers are urgently needed. This study evaluated the diagnostic value of CSF growth differentiation factor 15 (GDF15) in LM from lung adenocarcinoma (LUAD) and breast cancer (BC). - Source: PubMed
Publication date: 2026/09/22
Ruan HaoyuLi JieWang FuhaiZhang LeiLuo JieMu YuanWang TingWu YuqingLiu JingpingNing YunyunDeng XuanGuan MingXu Jian - Colorectal cancer (CRC) remains a leading cause of cancer mortality globally, with therapeutic efficacy hindered by tumor heterogeneity and drug resistance. While organoid technology offers unprecedented opportunities to model tumor complexity, systematic platforms for chemo-targeted combination screening and molecular mechanisms underlying chemoresistance remain underexplored in Chinese populations. Here, we established a biobank of 17 patient-derived CRC organoids (85% success rate) from treatment-naïve surgical specimens, preserving histopathological fidelity and molecular diversity of parental tumors. High-throughput drug screening across eight clinical regimens revealed different responses. To dissect chemoresistance mechanisms, six organoids representing extreme phenotypes (three sensitive and three resistant, based on IC50 difference for irinotecan + raltitrexed) were selected from this cohort for single-cell transcriptomic analysis. Single-cell transcriptomics of irinotecan + raltitrexed-treated organoids identified chemoresistance-associated clonal expansion of epithelial subpopulations (cluster_0), characterized by overexpression of REG4/TFF1/TFF3 and epithelial keratins (KRT19/KRT8/KRT18). Intercellular network analysis revealed intra-epithelial communication as a resistance hub, mediated by 32 ligand-receptor pairs. Integration with TCGA-COAD cohort (n = 378) demonstrated intratumoral heterogeneity (ITH) score as an independent prognostic determinant, outperforming stemness/angiogenesis metrics. Machine learning consensus identified CEACAM6 and KRT19 as dual regulators of mortality and ITH through epithelial plasticity networks. Our multi-omics framework establishes organoid-guided chemoresistance mechanisms while proposing ITH quantification targeting as precision strategies. This study bridges critical gaps in CRC therapeutic personalization, offering clinically actionable insights for overcoming treatment failure. - Source: PubMed
Jing ChangwenWang ZhuoCao HaixiaZhang YuanHuang YuchunYu YuetongLi BingzheMa Rong - Systemic administration of bispecific T‑cell engagers (BiTEs) targeting CEACAM6 has shown therapeutic potential but is limited by on‑target/off‑tumor toxicity and short serum half‑life. To overcome these challenges, we engineered an oncolytic herpes simplex virus (oHSV) that delivers and locally produces anti‑CEACAM6/CD3 BiTE directly within the tumor microenvironment (oHSV‑anti‑CEA6/CD3). In immunocompetent mouse models of colon (CT26) and breast (4T1) cancer, a single intratumoral injection of oHSV‑anti‑CEA6/CD3 promoted tumor regression, increased infiltration of CD8⁺CD44⁺ T cells both locally and systemically, and induced durable antitumor immunity. When combined with PD‑1 blockade, this localized BiTE‑arming strategy synergistically enhanced therapeutic efficacy, leading to superior tumor control and long‑term immunological memory without additional toxicity. Mechanistically, the virus exerts a dual action: direct oncolysis and sustained in situ BiTE production, enabling targeted T‑cell activation and tumor elimination while limiting systemic BiTE exposure. Unlike previous reports of BiTE‑armed oncolytic viruses or simple combinations with immune checkpoint inhibitors, our approach leverages the oHSV platform to achieve spatiotemporally controlled T‑cell redirection coupled with virus‑mediated innate immune stimulation. This work provides a safe, effective, and readily translatable strategy for solid tumor immunotherapy. - Source: PubMed
Publication date: 2026/08/13
Zhang WeiweiDai ShuangFan HaohanYang NianXu LongLiu ZheranMin YuJiang ZhengZhou LiangxueYang HuiTong AipingPeng Xingchen - Lung cancer continues to be the leading cause of cancer-related deaths worldwide, primarily due to persistent challenges in early detection and the limited effectiveness of precision medicine. Although low-dose computed tomography (CT) has been widely implemented for lung cancer screening and has contributed to a measurable reduction in disease-specific mortality, its diagnostic accuracy is limited by its inability to reliably distinguish benign from malignant pulmonary nodules. Furthermore, the clinical standard for metabolic imagingF-fluorodeoxyglucose (F-FDG) positron emission tomography (PET)is significantly constrained by a high incidence of false-positive findings in patients with inflammatory conditions and frequent false-negative results in tumors exhibiting low glycolytic activity. To overcome these critical limitations, highly specific PET radiotracers have been developed to target immune checkpoints, cell surface receptors, and distinct features of the tumor microenvironment. These molecularly targeted probes offer improved biological specificity, enabling more precise visualization of tumor pathophysiology and supporting applications in early diagnosis, real-time treatment monitoring, and prognostic stratification. This review summarizes recent advances in targeted PET imaging and critically evaluates the potential of integrating these approaches with multimodal imaging, liquid biopsy, and artificial intelligence (AI)-driven radiomics to enhance diagnostic accuracy and inform therapeutic decision-making. By synthesizing key developments from both preclinical studies and clinical trials, we highlight the translational significance and future directions of target-specific PET tracers. Despite existing challenges related to tracer development, regulatory approval, and methodological standardization, the integration of next-generation whole-body PET systems with advanced artificial intelligence algorithms holds considerable promise for establishing molecular-targeted PET as a cornerstone of precision oncology in lung cancer management. - Source: PubMed
Publication date: 2026/02/13
Chen ChongyangPan DonghuiWang XinyuXu YupingYan JunjieWang LizhenYang Min